| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 产品销售(元) | 150,684,537.88 | 301,569,922.54 | 146,247,537.37 | 287,365,318.75 |
| 医药研发与定制化生产(元) | 7,435,009.39 | 14,719,801.74 | 8,548,543.56 | 19,851,243.85 |
| 营业成本(元) | ||||
| 产品销售(元) | 49,076,543.25 | 64,368,229.81 | 29,861,386.76 | 72,125,684.28 |
| 医药研发与定制化生产(元) | 5,599,320.32 | 11,655,156.58 | 5,775,178.50 | 14,427,444.04 |
| 毛利(元) | ||||
| 产品销售(元) | 101,607,994.63 | 237,201,692.73 | 116,386,150.61 | 215,239,634.47 |
| 医药研发与定制化生产(元) | 1,835,689.07 | 3,064,645.16 | 2,773,365.06 | 5,423,799.81 |
| 毛利率(%) | ||||
| 产品销售(%) | 67.43 | 78.66 | 79.58 | 74.90 |
| 医药研发与定制化生产(%) | 24.69 | 20.82 | 32.44 | 27.32 |
| 收入构成(%) | ||||
| 产品销售(%) | 95.30 | 95.35 | 94.48 | 93.54 |
| 医药研发与定制化生产(%) | 4.70 | 4.65 | 5.52 | 6.46 |
| 毛利构成(%) | ||||
| 产品销售(%) | 98.23 | 98.72 | 97.67 | 97.54 |
| 医药研发与定制化生产(%) | 1.77 | 1.28 | 2.33 | 2.46 |